Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.57 |
| ▸ | MMP9 | P14780 | 5/20 | 0.57 |
| ▸ | MMP8 | P22894 | 5/20 | 0.57 |
| ▸ | MMP13 | P45452 | 5/20 | 0.57 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149005 | 0.90 | MMP2 (0.69) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL4142862 | 0.89 | MMP2 (0.60) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL13741444 | 0.87 | KDM4E (0.52) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL4152066 | 0.86 | MMP2 (0.46) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL4151626 | 0.86 | AURKA (0.43) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL4156776 | 0.85 | NPBWR1 (0.51) | DGAT1KCNH2SOAT1EGLN1 | |
| SCHEMBL15252345 | 0.85 | MMP2 (0.49) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL4153308 | 0.85 | METAP2 (0.48) | DGAT1KCNH2SOAT1CHEK2CYP2C8 | |
| SCHEMBL4149283 | 0.85 | DHODH (0.44) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL4147032 | 0.83 | CBFB (0.47) | MMP2MMP9MMP8MMP13DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | claimed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | claimed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8436022-B2 | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | TRPV1, TRPV3, TRPV5 | MMP2 1846/4885MMP9 3310/4885MMP8 673/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | MMP2 2548/4885MMP9 4054/4885MMP8 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.